J&J $5.5B talc settlement
Analysis based on 82 articles · First reported Jul 27, 2026 · Last updated Jul 30, 2026
The settlement removes a major legal overhang for Johnson & Johnson, potentially boosting investor confidence and stock price. However, the $5.5 billion payout and ongoing litigation in the UK may temper positive sentiment.
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires approval from at least 95% of claimants and would cover nearly all remaining talc claims in U.S. federal and state courts. J&J expects to make an initial payment of up to $3 billion in 2027, with additional payments in 2028. The company continues to deny the allegations, stating that scientific evidence supports the safety of its talc products. The settlement follows a series of courtroom victories for J&J, including a recent federal judge's ruling questioning plaintiffs' ability to prove specific causation. J&J previously settled most mesothelioma claims and state consumer protection cases. The company discontinued talc-based baby powder globally in 2023 and retained talc liabilities after spinning off its consumer health business into Kenvue. The settlement does not cover future lawsuits or claims in the United Kingdom.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard